| First Author | Hashimoto H | Year | 2016 |
| Journal | Biochem Biophys Res Commun | Volume | 478 |
| Issue | 3 | Pages | 1254-60 |
| PubMed ID | 27545600 | Mgi Jnum | J:238934 |
| Mgi Id | MGI:5824602 | Doi | 10.1016/j.bbrc.2016.08.104 |
| Citation | Hashimoto H, et al. (2016) Study on AAV-mediated gene therapy for diabetes in humanized liver mouse to predict efficacy in humans. Biochem Biophys Res Commun 478(3):1254-60 |
| abstractText | Most in vivo studies on the conversion to insulin-producing cells with AAV carrying PDX1 gene are performed in rodents. However, there is little information regarding Adeno-associated virus (AAV) carrying PDX1 gene transduced to human liver in vivo because accidental death caused by unpredicted factors cannot be denied, such as the hypoglycemic agent troglitazone with hepatic failure. Here we aim to confirm insulin secretion from human liver transduced with AAV carrying PDX1 gene in vivo and any secondary effect using a humanized liver mouse. As the results, AAV2-PG succeeded to improve the hyperglycemia of STZ-induced diabetic humanized liver mice. Then, the analysis of humanized liver mice revealed that the AAV2-PG was more transducible to humanized liver area than to mouse liver area. In conclusion, the humanized liver mouse model could be used to examine AAV transduction of human hepatocytes in vivo and better predict clinical transduction efficiency than nonhumanized mice. |
